$STIM

Neuronetics Flat on Opening New Facility

Neuronetics (NASDAQ: STIM) said it held the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. The nearly 7,000-square-foot facility, overseen by Neuronetics CEO Geoffrey Grammer, is described as the largest Greenbrook center to date and intended to expand access to interventional psychiatry and support clinical innovation.

Original reporting
Published Jul 28, 2026, 4:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Neuronetics Flat on Opening New Facility — source image
Decision brief

The 30-second read

$STIMNeutralLow
01

Why it matters

This is a facility expansion announcement. The text emphasizes future access, clinical innovation, and improved outcomes but does not provide financial or clinical performance data.

02

Market read

A PR-style expansion update that may support longer-term narrative, but lacks quantified catalysts for trading decisions.

03

What to watch

Traders would need follow-on disclosures on utilization, reimbursement rates, and whether the center supports any new treatment modalities with demonstrated outcomes.

Relevance 4/10Novelty 3/10Timing: today’s PR about a new facility opening

Background

Neuronetics is positioning interventional psychiatry delivery through Greenbrook’s National Center of Excellence model.

Company-level read

Ticker impact

$STIMNeutralMedium confidence
Context

Neuronetics announced the grand opening of a Greenbrook National Center of Excellence facility in Rockville, Maryland, overseen by its CEO.

Expected impact

Likely limited near-term impact unless follow-on disclosures tie the facility to measurable revenue, reimbursement, or trial/clinical results.

Evidence & confidence

A facility grand opening can support longer-term growth narrative, but the text provides no new numbers (revenue, margins, patient volumes, contracts) or regulatory/clinical catalysts.

Market effects

Could modestly reinforce sentiment around interventional psychiatry expansion and in-office treatment models, but without hard data it is not a sector reset.

Local healthcare footprint in Maryland, unlikely to move broader regional markets.

Primarily US-focused expansion story with no international implications mentioned.

Counterpoint

The “largest center to date” framing may be more marketing than value creation if it does not translate into measurable patient throughput or payer coverage.

Key entities

  • Neuronetics, Inc.

    NASDAQ-listed company (STIM) announcing the grand opening of a Greenbrook National Center of Excellence facility.

  • Greenbrook Mental Wellness Centers

    Operator of the National Center of Excellence facility being opened in Rockville, Maryland.

  • Geoffrey Grammer

    Neuronetics CEO overseeing the facility opening.

Related articles

$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

$STIMHighAI 8/10

Why is Neuronetics stock surging today?

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

$STIMMed

Neuronetics, Inc. (STIM): Results of Operations and Financial Condition

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar ® TMS technology with direc